


Peakdale Chemistry Services Limited
Annual report and unaudited financial statements
for the year ended 31 December 2022

Registered number: 07046734



Peakdale Chemistry Services Limited

Contents

	Page
Directors' report	3
Statement of financial position	4
Notes to the financial statements	5

Concept Life Sciences Integrated Discovery & Development Services Limited

Strategic report (continued)

The Directors' present their report and the unaudited financial statements of Peakdale Chemistry Services Limited (the "Company") for the year ended 31 December 2022. The Company has taken advantage of the exemption to prepare a Strategic Report under section 414B of the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013.

Business review and principal activities

The Company has not traded during the current or prior period. The Directors do not expect that this position will change in the foreseeable future. The Company is a dormant company in terms of section 1169 of the Companies Act 2006.

Directors' responsibilities

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

Going concern

As described in the accounting policies, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Directors

The Directors, who served throughout the period and thereafter, were as follows:

M Carnegie-Brown (resigned 31st March 2023)

SFA Horder (resigned 30th August 2022)

S Blair (resigned 31st March 2023)

Dr B Cliff (appointed 31st March 2023)

Exemption from audit

For the year ended 31 December 2022, the Company was entitled to exemption from audit under section 480 of the Companies Act 2006. The members have not required the Company to obtain an audit of its accounts for the year, in accordance with section 476 of the Companies Act 2006.

Approval

Approved by the Board and signed on its behalf by:



Dr B Cliff

Director

Date: 27 July 2023

Peakdale Chemistry Services Limited

Statement of financial position

As at 31 December 2022

	Note	2022 £	2021 £
Current assets			
Trade and other receivables	2	100	100
Net assets		<u>100</u>	<u>100</u>
Capital and reserves			
Called-up share capital	3	100	100
Profit and loss account		-	-
Shareholders' funds		<u>100</u>	<u>100</u>

Registered number: 07046734

For the financial period ended 31 December 2022, the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The Directors:

- confirm that members have not required the Company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements of Peakdale Chemistry Services Limited were approved by the Board of Directors and authorised for issue on 27th July 2023. They were signed on its behalf by:



Dr B Cliff
Director

Peakdale Chemistry Services Limited

Notes to the financial statements

As at 31 December 2022

1. Accounting policies

Peakdale Chemistry Services Limited (the "Company") is a company incorporated and domiciled in the UK.

Basis of preparation

These financial statements were prepared in accordance with Financial Reporting Standard 101 *Reduced Disclosure Framework* ("FRS 101").

The Company's ultimate parent undertaking, Spectris plc includes the Company in its consolidated financial statements. The consolidated financial statements of Spectris plc are prepared in accordance with International Financial Reporting Standards as adopted by the EU, and are available to the public as set out in note 4.

The financial statements are prepared on the historical cost basis.

These financial statements are presented in pounds sterling.

The preparation of financial statements in conformity with FRS 101 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

Going concern

The Company has not traded during the current period. The Directors do not expect that this position will change in the foreseeable future. The Directors expect to be able to operate within the level of its current resources to meet current obligations. Consequently, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

2. Debtors

	2022 £	2021 £
Amounts owed by Group undertakings	100	100

3. Called-up share capital

	2022 £	2021 £
Allotted, called-up and fully-paid 100 ordinary shares of £1 each	100	100

4. Parent and Ultimate Controlling Party

At 31 December 2022, Concept Life Sciences Integrated Discovery & Development Services Limited was the immediate parent and Spectris plc, a company listed on the London Stock Exchange was the ultimate holding company.

Spectris plc, is the largest and smallest group in which the results of the Company are consolidated. The consolidated accounts of this company may be obtained from Spectris plc, Melbourne House, 44-46 Aldwych, London, WC2B 4LL.